Pneumonia News and Research

Latest Pneumonia News and Research

SuperGen encouraged by Eisai's intent to file Dacogen sNDA for new indication

SuperGen, Inc., a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, announced that Eisai Inc. today released information regarding a randomized Phase III clinical trial of Dacogen® (decitabine) for Injection in elderly patients with acute myeloid leukemia (AML). The comparator in this trial was low-dose cytarabine, a chemotherapy agent, or supportive care.

30 Jun 2010

Cubist Phase 2 trial for efficacy of CXA-101 in complicated urinary tract infections meets objectives

Cubist Pharmaceuticals, Inc., a leading acute care therapeutics company, today announced that the recently-completed Phase 2 study of CXA-101, a novel cephalosporin, compared to ceftazidime for the treatment of complicated urinary tract infections (cUTI) in adults met its study objectives.

30 Jun 2010

Successful growth of mouse embryonic stem cells in rat lungs raises hopes for engineering human transplants

For someone with a severe, incurable lung disorder such as cystic fibrosis or chronic obstructive pulmonary disease, a lung transplant may be the only chance for survival. Unfortunately, it's often not a very good chance. Matching donor lungs are rare, and many would-be recipients die waiting for the transplants that could save their lives.

29 Jun 2010

AlphaRx regains all rights to Indaflex from Cypress Bioscience

AlphaRx, Inc. today announced that it has entered into an agreement with Cypress Bioscience, under which AlphaRx is regaining all rights to Indaflex(TM) from Cypress Bioscience, which AlphaRx had previously licensed to Proprius Pharmaceuticals, which was subsequently acquired by Cypress Bioscience.

29 Jun 2010

Health Canada recommends new pneumococcal vaccine for young children

In December, 2009, Health Canada approved a new vaccine for children aged six weeks through five years to prevent infections caused by the bacteria called pneumococcus or Streptococcus.

29 Jun 2010

Hospice care falls as more Americans spend final days in hospitals; Milwaukee hospital reports success with treatment guidelines

The Associated Press: "Americans increasingly are treated to death, spending more time in hospitals in their final days, trying last-ditch treatments that often buy only weeks of time, and racking up bills that have made medical care a leading cause of bankruptcies. More than 80 percent of people who die in the United States have a long, progressive illness such as cancer, heart failure or Alzheimer's disease."

29 Jun 2010

Lantus and Apidra injections improve glycemic control, reduce hospital complications: Study

Sanofi-aventis announced today that results from the RAndomized Study of Basal Bolus Insulin Therapy in the Inpatient Management of Patients with Type 2 Diabetes Undergoing General Surgery (RABBIT-2 Surgery) found that treatment with a basal-bolus regimen that included Lantus (insulin glargine [rDNA origin] injection) once-daily and Apidra (insulin glulisine [rDNA origin] injection) before meals improved glycemic control and reduced hospital complications, compared to "sliding scale" insulin in general surgery patients with type 2 diabetes.

28 Jun 2010

CHMP adopts positive opinion on pending MAA for SYCREST sublingual tablets

Merck announced that the Committee for Medicinal Products for Human Use adopted a positive opinion on the pending Marketing Authorization Application for SYCREST (asenapine) sublingual tablets. The CHMP has recommended that the European Commission grant a marketing authorization for SYCREST for the treatment of moderate to severe manic episodes associated with bipolar I disorder in adults. The CHMP did not support an indication for the treatment of schizophrenia.

25 Jun 2010

HealthGrades study examines mortality rates for patients entering hospitals through emergency departments

The quality of emergency medical care at the nation's hospitals varies widely - both individually and by state - according to a new HealthGrades study released today that, for the first time, examines mortality rates for patients entering hospitals through emergency departments.

23 Jun 2010

Pfizer to discontinue commercial availability of Mylotarg for AML in U.S.

Pfizer Inc. announced today that based on discussions with the U.S. Food and Drug Administration (FDA), it will be discontinuing commercial availability of Mylotarg® (gemtuzumab ozogamicin for Injection) (used for the treatment of relapsed acute myeloid leukemia (AML)) in the United States and that it will be voluntarily withdrawing the new drug application (NDA) for Mylotarg effective October 15, 2010.

22 Jun 2010

Asthmatics to suffer more this winter warn experts

Asthma sufferers in Australia have been warned about a bad cold and flu season ahead. 58 percent of the susceptible population is already experiencing asthma attacks since the start of the season according to The National Asthma Council Australia (NACA) on Monday. They went on to say that nearly half of this population is still not vaccinated against seasonal flu.

21 Jun 2010

Model Formulary for Children provides information on how to use over 240 essential medicines

The first ever WHO Model Formulary for Children released by the WHO provides information on how to use over 240 essential medicines for treating illness and disease in children from 0 to 12 years of age. This means that for the first time medical practitioners worldwide have access to standardized information on the recommended use, dosage, adverse effects, and contraindications of these medicines for use in children.

18 Jun 2010

Yearlong collaborative partnership launched to reduce hospital readmissions due to heart failure

More than 5 million individuals in the United States suffer from chronic heart failure, making it one of the most common reasons for hospitalizations and readmissions. To address this costly issue, the New Jersey Hospital Association's Institute for Quality and Patient Safety this week launched a yearlong collaborative partnership to reduce hospital readmissions due to heart failure and improve the quality of healthcare in New Jersey.

18 Jun 2010

Alkermes receives tentative schedule notification for FDA advisory committee meeting on VIVITROL sNDA

Alkermes, Inc. today announced that the U.S. Food and Drug Administration (FDA) has notified the company of the tentative scheduling of a Psychopharmacologic Drugs Advisory Committee meeting on September 16, 2010, for the review of the company's supplemental New Drug Application (sNDA) for VIVITROL® (naltrexone for extended-release injectable suspension) for opioid dependence.

18 Jun 2010

Daily use of probiotics reduces VAP in critically ill patients: New research

Daily use of probiotics reduced ventilator-associated pneumonia in critically ill patients by almost half, according to new research from Creighton University School of Medicine in Omaha, Nebraska.

17 Jun 2010

Financial Times examines how GAVI's $2.6B shortfall might affect new vaccine programs in developing countries

GAVI Alliance's plan to introduce new vaccine projects in the developing world "is under threat amid the international economic downturn," the Financial Times reports. "Subsidies to extend the use of vaccines against rubella, HPV to tackle cervical cancer, cholera and Japanese encephalitis in the developing world are among those likely to be cancelled or delayed," according to GAVI's CEO Julian Lob-Levyt, the newspaper writes.

17 Jun 2010

Also in Global Health News: Clinton to Haiti; Global Fund suspends Zambian aid; Ugandan health workers; MDG summit; Rwandan health insurance; HIV drugs in Kenya

Reuters reports that former President Bill Clinton will return to Haiti to "jump-start" the country's post-earthquake reconstruction. Clinton will head the first meeting of Haiti's reconstruction commission, "part of a sorely needed effort to better coordinate international aid efforts, [Prime Minister Jean-Max] Bellerive said." Bellerive hopes the meeting will "establish clear-cut guidelines" for distributing more than $5 billion in aid from 140 countries following the Jan. 12 earthquake (Brown, 6/16).

16 Jun 2010

Effective antimicrobial products can reduce hospital-acquired infections

The Centers for Disease Control estimate that more than two million people in the United States are affected annually by hospital-acquired infections. Meanwhile, a report released in April by the Agency for Healthcare Research and Quality concluded that this problem, which is worsening, requires urgent attention.

14 Jun 2010

Zargis Medical signs exclusive license agreement with Boston-based Stethographics

Zargis Medical Corp., a majority-owned subsidiary of Speedus Corp., today announced that it has entered into an agreement with Boston-based Stethographics, Inc. providing an exclusive license to patented, FDA-cleared Stethographics lung sounds analysis technology that automatically identifies clinically significant respiratory sounds.

11 Jun 2010

Cubist to oppose Teva’s attempt to add new defense in patent infringement litigation

Cubist Pharmaceuticals, Inc. today announced that it will oppose a motion filed by the Teva defendants to amend their answer to add a new defense in the patent litigation between Cubist and Teva pending in the US District Court for the District of Delaware. A motion for leave to amend the answer is a request to be permitted to add a new allegation. The Teva defendants seek leave to amend their answer to allege that US Patent Nos. 6,468,967 and 6,852,689 are unenforceable due to inequitable conduct.

11 Jun 2010

Pneumonia News and Research

Latest Pneumonia News and Research

SuperGen encouraged by Eisai's intent to file Dacogen sNDA for new indication

Cubist Phase 2 trial for efficacy of CXA-101 in complicated urinary tract infections meets objectives

Successful growth of mouse embryonic stem cells in rat lungs raises hopes for engineering human transplants

AlphaRx regains all rights to Indaflex from Cypress Bioscience

Health Canada recommends new pneumococcal vaccine for young children

Hospice care falls as more Americans spend final days in hospitals; Milwaukee hospital reports success with treatment guidelines

Lantus and Apidra injections improve glycemic control, reduce hospital complications: Study

CHMP adopts positive opinion on pending MAA for SYCREST sublingual tablets

HealthGrades study examines mortality rates for patients entering hospitals through emergency departments

Pfizer to discontinue commercial availability of Mylotarg for AML in U.S.

Asthmatics to suffer more this winter warn experts

Model Formulary for Children provides information on how to use over 240 essential medicines

Yearlong collaborative partnership launched to reduce hospital readmissions due to heart failure

Alkermes receives tentative schedule notification for FDA advisory committee meeting on VIVITROL sNDA

Daily use of probiotics reduces VAP in critically ill patients: New research

Financial Times examines how GAVI's $2.6B shortfall might affect new vaccine programs in developing countries

Also in Global Health News: Clinton to Haiti; Global Fund suspends Zambian aid; Ugandan health workers; MDG summit; Rwandan health insurance; HIV drugs in Kenya

Effective antimicrobial products can reduce hospital-acquired infections

Zargis Medical signs exclusive license agreement with Boston-based Stethographics

Cubist to oppose Teva’s attempt to add new defense in patent infringement litigation

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Pneumonia News and Research

Latest Pneumonia News and Research

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in